Cidara Therapeutics, Inc.

NasdaqCM:CDTX Voorraadrapport

Marktkapitalisatie: US$91.7m

Cidara Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Cidara Therapeutics is Jeff Stein, benoemd in Jan2014, heeft een ambtstermijn van 10.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.56M, bestaande uit 38.1% salaris en 61.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.03% van de aandelen van het bedrijf, ter waarde $ 948.36K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 3.8 jaar.

Belangrijke informatie

Jeff Stein

Algemeen directeur

US$1.6m

Totale compensatie

Percentage CEO-salaris38.1%
Dienstverband CEO10.8yrs
Eigendom CEO1.0%
Management gemiddelde ambtstermijn3.5yrs
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14
We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara spikes on $11M milestone payment from partner Mundipharma

Oct 04

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Sep 13

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17
Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17
Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04
Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

Analyse CEO-vergoeding

Hoe is Jeff Stein's beloning veranderd ten opzichte van Cidara Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$112m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$2mUS$594k

-US$23m

Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$1mUS$566k

-US$34m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$2mUS$566k

-US$42m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$1mUS$542k

-US$75m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$47m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$526k

-US$41m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$1mUS$501k

-US$69m

Sep 30 2018n/an/a

-US$70m

Jun 30 2018n/an/a

-US$69m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$2mUS$460k

-US$56m

Compensatie versus markt: De totale vergoeding ($USD 1.56M ) Jeff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Jeff is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jeff Stein (69 yo)

10.8yrs

Tenure

US$1,558,544

Compensatie

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jeffrey Stein
President10.8yrsUS$1.56m1.03%
$ 948.4k
Shane Ward
COO & Corporate Secretary3.3yrsUS$929.86k0.073%
$ 66.9k
Taylor Sandison
Chief Medical Officer8.2yrsUS$884.09k0.18%
$ 166.7k
Kevin Forrest
Founder & Chief Strategy Officerno dataUS$613.24kgeen gegevens
Preetam Shah
CFO & Principal Accounting Officer3.2yrsUS$683.71k0.11%
$ 97.9k
Allison Lewis
Senior Vice President of People & Culture3.8yrsgeen gegevensgeen gegevens
Leslie Tari
Chief Scientific Officer5.7yrsUS$1.39m0.12%
$ 109.8k
Nicole Davarpanah
Senior VP of Translational Research & Development1.3yrsgeen gegevensgeen gegevens
Jim Beitel
Chief Business Officerless than a yeargeen gegevensgeen gegevens

3.5yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CDTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jeffrey Stein
President10.8yrsUS$1.56m1.03%
$ 948.4k
Daniel Burgess
Independent Chairman of the Board10.6yrsUS$126.84k0.0021%
$ 2.0k
Theodore Schroeder
Independent Director10.6yrsUS$98.84k0%
$ 0
Frederick Hayden
Member of the Scientific Advisory Board4.3yrsgeen gegevensgeen gegevens
Bonnie Bassler
Independent Director3.8yrsUS$86.84k0.00021%
$ 192.6
Carin Canale-Theakston
Independent Director3.8yrsUS$82.34k0%
$ 0
Chrysa Mineo
Independent Director6.7yrsUS$91.34k0%
$ 0
Ryan Spencer
Independent Directorless than a yeargeen gegevensgeen gegevens
James Merson
Independent Directorless than a yeargeen gegevensgeen gegevens
Laura Tadvalkar
Independent Directorless than a yeargeen gegevensgeen gegevens
Mario Barro
Member of Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Philip Krause
Member of Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CDTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).